Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1676
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2493
    -0.0018 (-0.14%)
     
  • Bitcoin GBP

    51,078.02
    -665.74 (-1.29%)
     
  • CMC Crypto 200

    1,330.64
    -65.90 (-4.72%)
     
  • S&P 500

    5,105.09
    +56.67 (+1.12%)
     
  • DOW

    38,266.26
    +180.46 (+0.47%)
     
  • CRUDE OIL

    83.64
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron

Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron

Shares of Emergent Biosolutions (NYSE: EBS) and Regeneron (NASDAQ: REGN) have risen sharply in 2020 thanks to potential coronavirus drugs in development, but that's where their similarities end. Is Emergent, a company with government contracts to produce vaccines for other drugmakers, a better stock to buy now than Regeneron, a biotechnology pioneer with several blockbuster drugs under its belt? Over the past decade, Emergent Biosolutions has become the U.S. government's favorite contractor for infectious disease catastrophe preparation services.